Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals logo
$8.34 +0.68 (+8.88%)
Closing price 04:00 PM Eastern
Extended Trading
$8.19 -0.15 (-1.82%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXRX vs. RDY, SRPT, PCVX, QGEN, ROIV, ASND, RVMD, LEGN, BPMC, and AXSM

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Legend Biotech (LEGN), Blueprint Medicines (BPMC), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

Recursion Pharmaceuticals vs.

Recursion Pharmaceuticals (NASDAQ:RXRX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Dr. Reddy's Laboratories received 291 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 59.33% of users gave Dr. Reddy's Laboratories an outperform vote while only 57.69% of users gave Recursion Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Recursion PharmaceuticalsOutperform Votes
30
57.69%
Underperform Votes
22
42.31%
Dr. Reddy's LaboratoriesOutperform Votes
321
59.33%
Underperform Votes
220
40.67%

Dr. Reddy's Laboratories has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$44.58M68.53-$328.07M-$1.53-5.11
Dr. Reddy's Laboratories$3.35B3.43$668M$0.6321.93

Recursion Pharmaceuticals presently has a consensus price target of $8.75, indicating a potential upside of 11.91%. Dr. Reddy's Laboratories has a consensus price target of $17.00, indicating a potential upside of 23.41%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Recursion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Dr. Reddy's Laboratories
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 12 articles in the media. Recursion Pharmaceuticals' average media sentiment score of 0.88 beat Dr. Reddy's Laboratories' score of 0.35 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dr. Reddy's Laboratories
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Dr. Reddy's Laboratories has a net margin of 17.25% compared to Recursion Pharmaceuticals' net margin of -579.52%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-579.52% -76.56% -55.68%
Dr. Reddy's Laboratories 17.25%17.87%12.32%

Summary

Dr. Reddy's Laboratories beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.06B$3.07B$5.68B$9.00B
Dividend YieldN/A1.79%5.32%4.00%
P/E Ratio-5.1145.8687.3919.27
Price / Sales68.53318.721,048.5074.40
Price / CashN/A192.7646.0938.87
Price / Book3.953.935.054.98
Net Income-$328.07M-$40.60M$113.45M$222.68M
7 Day Performance-1.28%-6.35%-1.94%-1.16%
1 Month Performance13.65%-2.71%2.98%2.29%
1 Year Performance-28.53%-10.55%21.12%17.27%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
1.628 of 5 stars
$8.34
+8.9%
$8.75
+4.9%
-24.1%$3.26B$44.58M-5.45400Gap Down
RDY
Dr. Reddy's Laboratories
2.0849 of 5 stars
$13.80
-0.7%
$17.00
+23.2%
-6.8%$11.52B$3.35B21.9727,048Short Interest ↑
Analyst Revision
SRPT
Sarepta Therapeutics
4.6757 of 5 stars
$113.57
+1.6%
$178.71
+57.4%
-13.5%$10.83B$1.24B90.681,314Analyst Forecast
PCVX
Vaxcyte
2.5806 of 5 stars
$86.19
-1.4%
$145.71
+69.1%
+13.8%$10.76BN/A-18.77160Analyst Forecast
QGEN
Qiagen
4.3624 of 5 stars
$40.30
-2.5%
$48.78
+21.1%
-9.0%$8.96B$1.98B112.455,967Earnings Report
Analyst Revision
ROIV
Roivant Sciences
3.6788 of 5 stars
$10.92
+0.2%
$17.93
+64.3%
-3.0%$7.97B$124.79M1.94860Earnings Report
Analyst Forecast
ASND
Ascendis Pharma A/S
3.0482 of 5 stars
$120.89
+0.0%
$191.57
+58.5%
-15.7%$7.34B$288.08M-14.96640Earnings Report
Analyst Forecast
News Coverage
RVMD
Revolution Medicines
4.5176 of 5 stars
$42.27
+0.2%
$66.25
+56.7%
+36.2%$7.13B$11.58M-11.80250Positive News
LEGN
Legend Biotech
2.5696 of 5 stars
$35.87
+1.4%
$79.50
+121.7%
-43.2%$6.56B$285.14M-37.831,800
BPMC
Blueprint Medicines
2.1135 of 5 stars
$102.90
-2.0%
$123.72
+20.2%
+32.7%$6.53B$434.42M-48.73640Short Interest ↓
Analyst Revision
Gap Down
AXSM
Axsome Therapeutics
4.4497 of 5 stars
$129.85
+22.8%
$134.00
+3.2%
+36.4%$6.32B$270.60M-19.97380Upcoming Earnings
Analyst Forecast
Analyst Revision
News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners